Astegolimab: meta-analysis of COVID-19 studies

All studies   Mortality   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -31% 1 264 Improvement, Studies, Patients Relative Risk Mortality -31% 1 264 RCTs -31% 1 264 Late -31% 1 264 Astegolimab for COVID-19 c19early.org December 2025 Favorsastegolimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) 1% 0.99 [0.74-1.33] no recov. 130 (n) 134 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.95 Late treatment 1% 0.99 [0.74-1.33] 130 (n) 134 (n) 1% lower risk All studies 1% 0.99 [0.74-1.33] 130 (n) 134 (n) 1% lower risk 1 astegolimab COVID-19 recovery result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.95 Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Late treatment -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk All studies -31% 1.31 [0.69-2.33] 19/130 15/134 31% higher risk 1 astegolimab COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.41 Effect extraction pre-specified(most serious outcome) Favors astegolimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -31% 1.31 [0.69-2.33] death 19/130 15/134 Improvement, RR [CI] Treatment Control COVASTIL Waters (DB RCT) 1% 0.99 [0.74-1.33] no recov. 130 (n) 134 (n) Astegolimab COVID-19 outcomes c19early.org December 2025 Favors astegolimab Favors control